Back to journals
Academic Journal

Psychiatry Research

25 Papers Indexed in Blossom

Data updated

Research Footprint

Psychiatry Research has 25 tracked papers indexed in Blossom (2000–2026) from 197 authors, most often covering Ketamine, Psilocybin and MDMA, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).

Published Papers

Paywallindividual

Faster and greater antidepressant response to intravenous ketamine in bipolar compared with unipolar treatment-resistant depression: Diagnostic and sex-related findings from a naturalistic study

This observational study (n=97) examined intravenous ketamine for treatment-resistant unipolar and bipolar depression and found that symptoms improved in both groups, with faster and greater improvement in bipolar depression. Dissociative effects stayed stable overall, and sex differences in antidepressant response were not seen, although women with unipolar depression reported more dissociation at three months.

Published
Journal
Psychiatry Research
Authors
Carmellini, P., Fagiolini, A., Pinzi, M., Magno, M., Martella, D., Nicchi, L., Rescalli, M. B., Tarantino, F., Tinturini, R., Scheggi, S., Gualtieri, G., Cuomo, A.
Open Accessmeta

Psychedelics as a potential treatment for borderline personality disorder: A narrative review

This narrative review (s=22) examined studies of ketamine, esketamine and psilocybin in people with borderline personality disorder and found early evidence that they may help core symptoms and social and work functioning. It also noted that patients with BPD are often excluded from research because of safety concerns, especially around suicide and substance misuse.

Published
Journal
Psychiatry Research
Authors
Artna, E., Sandhu, G., Chisamore, N., Lipsitz, O., Kaczmarek, E. S., Johnson, D. E., Rosenblat, J. D., Sediqzadah, S.
Paywallmeta

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.

Published
Journal
Psychiatry Research
Authors
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., Nayak, S. M.
Open Accessindividual

IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital

This longitudinal study (n=71) examines five years of real-world clinical data on the use of IV low-dose ketamine alongside standard care for outpatients with depression (MDD & TRD). Results indicate a significant reduction in depressive symptoms and suicide ideation by treatment endpoint, with 55% of patients responding to treatment. Side effects were transient and mild for 78% of patients, with a dropout rate of 11%. Multivariate analysis suggests that demographic variables did not impact treatment efficacy or tolerability.

Published
Journal
Psychiatry Research
Authors
Gutierrez, G., Kang, M. J. Y., Vasquez, G.
Paywallindividual

Anti-suicidal effects of IV ketamine in a real-world setting

This community-based study (n=295) examined the impact of intravenous ketamine treatment on suicidality. Using growth mixture modelling, three trajectory groups were identified: one with moderate baseline scores showing gradual improvement (n=170, 57.6%), another with severe baseline scores showing no improvement (n=63, 21%), and a third with rapid improvement (n=62, 21%). Among clinical and demographic variables, only higher scores on active thoughts of death and/or plan predicted a lack of benefit from treatment for those with severe baseline CHRT-SR scores. The findings support ketamine's potential effectiveness in addressing suicidality in a proportion of patients.

Published
Journal
Psychiatry Research
Authors
O'Brien, B., Lee, J., Kim, S., Nandra, G. S., Pannu, P., Tamman, A. J. F., Amarneh, D., Swann, A. C., Murphy, N., Averill, L. A., Jha, M. K., Mathew, S. J.
Paywallmeta

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

This systematic review analyzed the effects of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. The review included 13 studies with a total of 686 participants, and the meta-analysis of 9 studies (596 participants) found a significant and large effect in favor of psilocybin (SMD = -0.78; p<0.001) for reducing depressive symptoms. The review suggests preliminary evidence supporting the antidepressant efficacy of psilocybin-assisted psychotherapy but calls for further studies to assess safety, efficacy, and treatment optimization.

Published
Journal
Psychiatry Research
Authors
Haikazian, S., Chen-Li, D., Johnson, D., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., Rosenblat, J. D.

Quick Facts

Papers Indexed
25
h-Index
187
Open Access
No
Publisher
Elsevier
Country
Ireland
Website
Visit